Upload File

tm national center on birth defects and developmental disabilities kernicterus surveillance...

  • Home
  • Documents
  • TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on
17
TM National Center on Birth Defects and National Center on Birth Defects and Developmental Disabilities Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on Current Epidemiology and Therapeutic Interventions Relevant to Hyperbilirubinemia in the Term & Near-term Newborn Washington DC: June 11, 2003

Upload: aldous-harris

Post on 02-Jan-2016

218 views

Category:

Documents


2 download

Report

TRANSCRIPT

Page 1: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

National Center on Birth Defects and Developmental DisabilitiesNational Center on Birth Defects and Developmental DisabilitiesNational Center on Birth Defects and Developmental DisabilitiesNational Center on Birth Defects and Developmental Disabilities

Kernicterus Surveillance Kernicterus Surveillance

Presented at the FDA Pediatric Advisory Committee Meeting onCurrent Epidemiology and Therapeutic Interventions Relevant to

Hyperbilirubinemia in the Term & Near-term NewbornWashington DC: June 11, 2003

Page 2: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Overview: Framework for DD surveillanceOverview: Framework for DD surveillance

• Health education & prevention strategies

• Public policy

• Monitor prevalence rates, trends, & prevention programs

• Provide registry of cases

Surveillance

Systems

Epidemiological Studies

Prevention Programs

• Identify risk & protective factors

• Address public concerns

Page 3: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Definitions– Attributable to an impairment in physical,

cognitive, speech or language, psychological, or self-care areas

Measurement – Not always straight forward, especially for

conditions that rely on a behavioral patterns Population-based– Limited surveillance and not always well defined

Above issues can make generalizing results difficult or impossible to interpret

Overview: Complexities of DD surveillanceOverview: Complexities of DD surveillance

Page 4: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Issues: Complexities of KI surveillanceIssues: Complexities of KI surveillance

Range of impairment and associated conditions– Brain damage that is associated with athetoid

cerebral palsy, hearing loss, vision impairment, dental dysplasia, and sometimes mental retardation

Changes in level of awareness and use of diagnosis over time

Variability in how cases are diagnosed– Physical markers and behavioral pattern utilized

for identification Early onset but often delayed diagnosis

Page 5: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

No systematic population-based surveillance in place to monitor kernicterus or hyperbilirubinemia

Case reports from convenience samples or select populations (e.g., medical insurance records)

No accepted standard for surveillance definition

Historical perspectives: KI surveillanceHistorical perspectives: KI surveillance

Page 6: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

True population estimates unknown to date Case reports from a convenience sample– Johnson, Bhutani, Brown (2002). 90 cases

reported from 1984-Jan 2001 Rates versus numbers

Prevalence of kernicterusPrevalence of kernicterus

– Rate = # of people with condition

# of people in the population Is kernicterus on the rise?

Page 7: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Summary of issues for KI surveillanceSummary of issues for KI surveillance

Case definition– Debate over cut-offs for inclusion

Low prevalence condition– Requires a substantial population to detect cases

Lack of recognition– Acute event with specific features– Permanent damage, long-term clinical features

Litigation– Possible deterrent for case identification

Page 8: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Evaluation of extant databases– National Hospital Discharge Data

Preponderance of hyperbilirubinemia codes KI codes not readily used

– MADDSP surveillance Examined athetoid CP cases

Kernicterus is not a reportable condition– CSTE approached regarding national reporting

Managed Care System– Proposed cooperative agreement– Limited interest

Preliminary actions: CDCPreliminary actions: CDC

Page 9: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

PERT announcement 2002 Objectives– Applicant should seek to review cases of extreme

jaundice in otherwise healthy full-term infants – Provide a body of evidence to inform why cases of

extreme jaundice may lead to kernicterus and why kernicterus may be re-emerging

– A forum of concerned scientists and health-care professionals will be convened to develop a strategic plan for national kernicterus prevention

Current activities: CDC surveillance effortsCurrent activities: CDC surveillance efforts

Page 10: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

UMDNJ Robert Wood Johnson Medical SchoolPrincipal Investigators: T. Hegyi, B. Ostfeld, A. Petrova

Infant mortality and morbidity of kernicterus Surveillance Identification of risk factors (clinical & systemic) Support network

Objectives of award recipientObjectives of award recipient

Page 11: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

UMDNJ Robert Wood Johnson Medical SchoolPrincipal Investigators: T. Hegyi, B. Ostfeld, A. Petrova

IRB submissions and approvals Initial discussion & process for population-based

surveillance with the NJ Dept of Health Analyses of extant data on infant morbidity and

mortality due to kernicterus

Progress to dateProgress to date

Page 12: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Preliminary results: MorbidityPreliminary results: Morbidity

UMDNJ Robert Wood Johnson Medical SchoolPrincipal Investigators: T. Hegyi, B. Ostfeld, A. Petrova

1992 – 2001(NJ Hospital Discharge Data)– 82 cases of kernicterus– 7.5/100,000 live births (cumulative incidence)– Significant variation by race and ethnicity with the

lowest rate among Hispanics and the highest rate among Asians

Page 13: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Pennsylvania Hospital, University of PennsylvaniaPrincipal Investigators: V. Bhutani & L. Johnson

Surveillance Identification of risk factors (clinical & systemic) Prevention Taskforce/Steering Committee National Prevention Campaign

Objectives of award recipientObjectives of award recipient

Page 14: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Pennsylvania Hospital, University of Pennsylvania Principal Investigators: V. Bhutani & L. Johnson

Initial Advisory Board teleconference Peer Review Group meeting for consensus on

kernicterus definition (planned) Database development Collaboration with PICK on kernicterus

educational video

Progress to dateProgress to date

Page 15: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Future directionsFuture directions

Partner for prevention– American Academy of Pediatrics, AWHONN,

HRSA, JCAHO, March of Dimes, NICHD, PICK, University researchers, others…

Forum for developing consensus on surveillance case definition

Identify a mechanism for population-based surveillance– State– National

Page 16: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM

Working to prevent kernicterusWorking to prevent kernicterus

Page 17: TM National Center on Birth Defects and Developmental Disabilities Kernicterus Surveillance Presented at the FDA Pediatric Advisory Committee Meeting on

TM


University of Groningen Oral treatment of unconjugated … · 2016-03-06 · bilirubin metabolism, unconjugated hyperbilirubinemia, Crigler-Najjar disease, kernicterus, current treatment

DHHS / FDA / CDRH 1 FDA Summary CryoLife BioGlue P010003 Lead FDA Reviewer Lisa Kennell

Neonatal Jaundice & Prolonged Jaundicehsibu.moh.gov.my/hsb.bm/wp-content/uploads/2017/04/Neonatal... · •Higher risk of Kernicterus –sepsis, prematurity, small for gestational

Crystal defects linear defects (dislocations)

FDA Perspective: FDA Evaluation of Point of Care … How FDA reviews...1 FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters Patricia Bernhardt, M.T.(ASCP), Scientific

EUV Defects – Kevin Cummingseuvlsymposium.lbl.gov/pdf/2009/pres/O_M2RI2-04... · Pos defects. Neg defects. Bridges. Gaps. Optimize inspection. on program defects. Resist. images

Molding Defects, Causes, & Corrective Actions...Molding Defects, Causes, Corrective Actions Possible Molding Defects Possible Molding Defects Possible Molding Defects Defect Description

UGT1A1-related Bilirubin Encephalopathy/Kernicterus in

THE EMERGENCY GUIDE TO FDA WARNING …€¦ · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDA Grop.com 1 THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 …

CLINICAL PRACTICE GUIDELINE - Ontario Midwives...jaundice’ (jaundice defined as: 1.kernicterus due to isoimmunization, other specified kernicterus, kernicterus, unspecified; 2. neonatal

KERNICTERUS.dm5migu4zj3pb.cloudfront.net/manuscripts/103000/103864/...kernicterus. Plasma concentrations of bilirubin exceeding 20 mg. per cent are considered levels above which kernicterus

KERNICTERUS AND PREMATURITYadc.bmj.com/content/archdischild/30/154/501.full.pdf · KERNICTERUS AND PREMATURITY BY V. M. CROSSE, T. C. MEYERand J. W. GERRARD FromSorrento MaternityHospital,

Kernicterus Developmental Pediatrics Louis Meng, PL2 November 12 th 2002

DEFECTS IN CRYSTALSeacharya.inflibnet.ac.in/data-server/eacharya... · DEFECTS IN CRYSTALS Point defects 0D Line defects 1D Surface Imperfections 2D Volume Defects 3D MATERIALS SCIENCE

Newborn Jaundice and the Prevention of Kernicterus plan. Lack of TSB/TcB measure jaundice progression. ... Lesson Learned: ... Revised guidance to help prevent kernicterus

FDA Oral History Interviews, FDA retired scientists

FDA Alliance for a Stronger FDA

HYPER-BILIRUNEMIA. History Earliest work on jaundice from Baumes-1785, and Hervieux-1847 Kernicterus was first described by Johannes Orth, 1875

FDA Presentation FDA Presentation

ENFERMEDAD HEMOLÍTICA DEL RECIEN NACIDO//dc406.4shared.com/doc/0p GIzdpQ/preview.html . Incompatibilidad sanguínea ... Ictericia y kernicterus Ictericia neonatal

Root Defects. Internal Defects. Surface Defects. عیوب ریشه عیوب میانی عیوب سطحی

DEFECTS IN CRYSTALS Point defects 0D Line defects 1D Surface Imperfections 2D Volume Defects 3D MATERIALS SCIENCE &ENGINEERING Anandh Subramaniam

Defects in solids: Point defects and line defects

Management of Auditory Neuropathy: Mission Impossible? · Management of Auditory Neuropathy: Mission Impossible? ... Bilirubinemia/ Kernicterus z ... Management of Auditory Neuropathy:

1959 Studies in Kernicterus the Protein Binding of Bilirubin

 · 2008-01-14 · DEFECTS FINISH DEFECTS NECK DEFECTS SHOULDER DEFECTS BODY DEFECTS BASE DEFECTS Innovative Inspection Technology Guide BROKEN WARE Ware which is cracked or broken

Kernicterus en México - Ministerio de Sanidad, Servicios ... · Más información. • 1. Parents of Infants and Children with Kernicterus, P.I.C.K´s web site: • 2. Pacientes

205750Orig1s000 - Food and Drug Administration...Feb 11, 2014  · Calbon . FDA . Drolban . FDA . Cholan-HBM . FDA . Cholesterol . External . Cholbam *** FDA . Clobazam . External,

Derailment Due to Wheel Defects Vehicle Defects

Screening to prevent kernicterus

22. Kernicterus - Shapiro - Children's Mercy Kansas · PDF file10/29/12 2 P.I.C.K. Parents of Infants and Children with Kernicterus Kernicterus, permanent brain damage due to excessive

KERNICTERUS AND PREMATURITY · KERNICTERUS AND PREMATURITY BY V. M. CROSSE, T. C. MEYERand J. W. GERRARD FromSorrento MaternityHospital, Birmingham (RECEIVED FOR PUBLICATION JUNE

THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 · 2018-12-13 · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDAGrop.com 4 FDA 483 RESOLVING FDA 483 OBSERVATIONS

Birth Defects Resulting From Single Gene Defects

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez)